Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al..
2004.
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.. Am J Pathol. 164(3):787-93.
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.
2016.
An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..
2008.
EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.
Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..
2013.
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.
Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..
2010.
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..
2008.
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.
Rubin MA.
2012.
ETS rearrangements in prostate cancer.. Asian J Androl. 14(3):393-9.
Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS et al..
2010.
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.. Genome Biol. 11(10):R104.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..
2011.
The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.
Barbieri CE, Rubin MA.
2015.
Genomic rearrangements in prostate cancer.. Curr Opin Urol. 25(1):71-6.
Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al..
2009.
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 27(21):3459-64.
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al..
2005.
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.. Cancer Res. 65(13):5561-70.
Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.
2004.
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.. J Natl Cancer Inst. 96(11):834-43.
Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..
2012.
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.